| Title | Blood cancer discovery |
| Abbreviation | Blood cancer discov. |
| Publication Type | Journal |
| Subject Area, Categories, Scope | Biochemistry, Genetics and Molecular Biology (miscellaneous) (Q1); Cancer Research (Q1); Hematology (Q1); Oncology (Q1) |
| h-index | 25 |
| Overall Rank/Ranking | 325 |
| SCImago Journal Rank (SJR) | 4.64 |
| Impact Score | 8.13 |
| Publisher | NLM (Medline) |
| Country | United States |
| ISSN | 26433230, 26433249 |
| Best Quartile | Q1 |
| Coverage History | 2020-2023 |
Blood cancer discovery is a journal covering the technologies/fields/categories related to Biochemistry, Genetics and Molecular Biology (miscellaneous) (Q1); Cancer Research (Q1); Hematology (Q1); Oncology (Q1). It is published by NLM (Medline). The overall rank of Blood cancer discovery is 325. According to SCImago Journal Rank (SJR), this journal is ranked 4.64. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come. SJR acts as an alternative to the Journal Impact Factor (or an average number of citations received in last 2 years). This journal has an h-index of 25. The best quartile for this journal is Q1.
The ISSN of Blood cancer discovery journal is 26433230, 26433249. An International Standard Serial Number (ISSN) is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic. Blood cancer discovery is cited by a total of 959 articles during the last 3 years (Preceding 2023).
The Impact IF 2023 of Blood cancer discovery is 8.13, which is computed in 2024 as per its definition. The impact IF, also denoted as Journal impact score (JIS), of an academic journal is a measure of the yearly average number of citations to recent articles published in that journal. It is based on Scopus data.
Impact IF 2023 of Blood cancer discovery is 8.13. If the same upward trend persists, Impact IF may rise in 2024 as well.
| Year | Impact IF |
|---|---|
| 2023/2024 | Coming Soon |
| 2023 | 8.13 |
Blood cancer discovery has an h-index of 25. It means 25 articles of this journal have more than 25 number of citations. The h-index is a way of measuring the productivity and citation impact of the publications. The h-index is defined as the maximum value of h such that the given journal/author has published h papers that have each been cited at least h number of times.
The ISSN of Blood cancer discovery is 26433230, 26433249. ISSN stands for International Standard Serial Number.
An ISSN is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic.
The overall rank of Blood cancer discovery is 325. According to SCImago Journal Rank (SJR), this journal is ranked 4.64. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come.
| Year | SJR |
|---|---|
| 2023/2024 | Coming Soon |
| 2023 | 4.64 |
| Year | Ranking |
|---|---|
| 2023/2024 | Coming Soon |
| 2023 | 325 |
Blood cancer discovery is published by NLM (Medline). It's publishing house is located in United States. Coverage history of this journal is as following: 2020-2023. The organization or individual who handles the printing and distribution of printed or digital publications is known as Publisher.
Visit the official website of the journal/conference to check the further details about the call for papers.
The IS0 4 standard abbreviation of Blood cancer discovery is Blood cancer discov.. This abbreviation ('Blood cancer discov.') is well recommended and approved for the purpose of indexing, abstraction, referencing and citing goals. It meets all the essential criteria of ISO 4 standard.
ISO 4 (International Organization for Standardization 4) is an international standard that defines a uniform and consistent system for abbreviating serial publication titles and journals.
If your research field is/are related to Biochemistry, Genetics and Molecular Biology (miscellaneous) (Q1); Cancer Research (Q1); Hematology (Q1); Oncology (Q1), then please visit the official website of this journal.
The acceptance rate/percentage of any academic journal/conference depends upon many parameters. Some of the critical parameters are listed below.
It is essential to understand that the acceptance rate/rejection rate of papers varies among journals. Some Journals considers all the manuscripts submissions as a basis of acceptance rate computation. On the other hand, few consider the only manuscripts sent for peer review or few even not bother about the accurate maintenance of total submissions. Hence, it can provide a rough estimation only.
The best way to find out the acceptance rate is to reach out to the associated editor or to check the official website of the Journal/Conference.
Blood cancer discovery latest impact IF is 8.13. It's evaluated in the year 2023. The highest and the lowest impact IF or impact score of this journal are 8.13 (2023) and 8.13 (2023), respectively, in the last 1 year. Moreover, its average IS is 8.13 in the previous 1 year.
The Blood cancer discovery has an SJR (SCImago Journal Rank) of 4.64, according to the latest data. It is computed in the year 2024. In the past 1 years, this journal has recorded a range of SJR, with the highest being 4.64 in 2023 and the lowest being 4.64 in 2023. Furthermore, the average SJR of the Blood cancer discovery over the previous 1-year period stands at 8.13.
The latest h-index of the Blood cancer discovery is 25.
The Blood cancer discovery is published by the NLM (Medline), with its country of publication being the United States.
The Blood cancer discovery is currently ranked 325 out of 27955 Journals, Conferences, and Book Series in the latest ranking. Over the course of the last 1 year, this journal has experienced varying rankings, reaching its highest position of 325 in 2023 and its lowest position of 325 in 2023.
The standard ISO4 abbreviation for the Blood cancer discovery is Blood cancer discov..
Blood cancer discovery is classified as a journal that the NLM (Medline) publishes.
The Blood cancer discovery encompasses the following areas:
For a more comprehensive understanding of its scope, check the official website of this journal.
The Blood cancer discovery is assigned the following International Standard Serial Numbers (ISSN): 26433230, 26433249.
The best quartile for the Blood cancer discovery is Q1 (2023).
The Blood cancer discovery coverage history can be summarized as follows: 2020-2023.
| Journal/Conference/Workshop/Book Title | Type | Ranking | Publisher | h-index | Impact Score |
|---|---|---|---|---|---|
| Dermatologia Kliniczna | journal | 25442 | Cornetis | 7 | 0.00 |
| Proceedings of the ASME Turbo Expo | conference and proceedings | 17577 | 54 | 0.00 | |
| Proceedings of the Spring Technical Conference of the ASME Internal Combustion Engine Division | conference and proceedings | 17477 | 16 | 0.00 | |
| Criminal Justice Review | journal | 12054 | SAGE Publications Inc. | 42 | 1.10 |
| International Journal of Parallel, Emergent and Distributed Systems | journal | 16153 | Taylor and Francis Ltd. | 25 | 1.10 |
| Abacus | journal | 5997 | Wiley-Blackwell Publishing Ltd | 53 | 2.75 |
| Sex Education | journal | 7722 | Routledge | 45 | 2.66 |
| Educational Measurement: Issues and Practice | journal | 5979 | Wiley-Blackwell Publishing Ltd | 64 | 1.67 |
| Korean Journal of Applied Microbiology and Biotechnology | journal | 22033 | Korean Society for Applied Microbiology | 0 | 0.00 |
| Acta Periodica Technologica | journal | 23723 | University of Novi Sad, Faculty of Technology | 21 | 0.31 |
| Year | Impact Score (IS) |
|---|---|
| 2024/2025 | Coming Soon |
| 2023 | 8.13 |
